Clinical Trial Detail

NCT ID NCT03005639
Title ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Inova Health Care Services
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST